{'fraction_non_alphanumeric': 0.031446540880503145, 'fraction_numerical': 0.012578616352201259, 'mean_word_length': 5.368, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A case of refractory T-cell lymphoblastic lymphoma coexisting with ZMYM2-fibroblastic growth factor receptor-1 fusion-related myeloproliferative disease and review of literatures

T-cell LBL (T-LBL) is a rare lymphoma subtype in adults, and it usually has a dismal prognosis compared to other subtypes of non-Hodgkin lymphoma. Here, we present a unique case of T-LBL with myeloproliferative disease. A distinct fusion gene of ZMYM2-FGFR1 translocation was detected through next-generation sequencing, and this might be correlated with the translocation of chromosomes 8 and 13 (t[8;13]). Her disease condition seemed to be refractory to multiple lines of chemotherapy. Her lymphoma finally achieved a complete remission after a matched related allogeneic hematopoietic stem cell transplantation.